Search

Service Type

Arrow Hook

Oncology

Chevron

All

Vector 4

Small Molecule

Antibody

Cancer Vaccine​

mRNA

Immune Cell​

TME – CAF

Zebrafish Drug Test

Immuno Oncology

Chevron

All

Vector 4

Macrophage

Regulatory T Cell

Tumor-Infiltrating Lymphocyte

Cytotoxic T Cell

Anti-Virus

Chevron

All

Vector 4

Coronavirus

Influenza Virus

HPV

Adenovirus

Disease Modeling

Chevron

All

Vector 4

GI Tract Disease Model

Gland Disease Model

Metabolic Disease Model

Brain & CNS Disease Model

Respiratory and ENT Disease

Cosmetics

Chevron

All

Vector 4

Brightening

Anti-Aging

Anti-Inflammation

Anti-Oxidant

Anti-Hair Loss

Hair Growth

Skin Irritation

Skin Barrier

Microbiome

Chevron

All

Vector 4

Probiotic Adhesion Assay (2D)

Host-Microbiome Study (3D)

Toxicity

Chevron

All

Vector 4

Organoid Based

OECD

Chevron

All

Vector 4

Eye Irritation

Skin Irritation

Phototoxicity Test

Skin Corrosion

Spatial Biology

Chevron

All

Vector 4

Protein Solution

RNA Solution

Technology Service

Chevron

All

Vector 4

CRISPR-Cas9

iPSC Generation

Viral Vector Cloning

Next-Generation Sequencing (NGS)

scRNA Sequence

Resource Type

Arrow Hook
Normal Organoid
Chevron

All

Vector 4

Intestinal Organoid

Skin & Hair Folicle Organoid

Kidney Organoid​

Cardiac Organoid

Salivary Gland Organoid​

Lacrimal Gland Organoid

Tonsil Organoid

Adenoid Organoid

Retinal Organoid

Lung Organoid

Cerebral Organoid

Midbrain Organoid

Liver Organoid

Cancer Organoid

Chevron

All

Vector 4

Colorectal Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Breast Cancer

Cholangiocarcinoma

Gastric Cancer

Ovarian Cancer

Hepatocarcinoma Cancer

Endometrial Cancer

Immune Cell

Chevron

All

Vector 4

Macrophage

Regulatory T Cell

Tumor-Infiltrating Lymphocyte

Cytotoxic T Cell

2D Cell

Chevron

All

Vector 4

Cancer Associate Fibroblast (CAF)

BALB 3T3

Melanocyte

MNT-1

B16F10

Melan-A

Spatial Biology

Chevron

All

Vector 4

CODEX

OPAL

Visium

GeoMX

Research Service

Chevron

All

Vector 4

CRISPR-Cas9

iPSC Generation

Viral Vector Cloning

Next-Generation Sequencing (NGS)

scRNA Sequence

Others

Chevron

All

Vector 4

Zebrafish

Egg

Cornea

Artificial Skin

Introduction

Arrow Hook

Event

Arrow Hook

Resources

BioArt

About

Contact Us

Get Started
Login
Cytotoxic T cell_main
Immune Cell

Cytotoxic T cell

6003€+
Immune Cell

Cytotoxic T cell

  • Tumor-Infiltrating Lymphocytes (TILs) are predominantly found in the microenvironment of tumors, including various types of lymphocytes that have infiltrated in and around tumor tissues.
  • Among them, CD8+ cytotoxic T cells and CD4+ helper T cells are major components.
  • Our approach involves isolating and expanding TILs from a patient’s tumor tissue, then evaluating the efficacy of anticancer agents in a tumor microenvironment containing cancer organoids and TILs.
Price
6003€+
Login to see price
Organism
Human
Product Type
Organoid + Cytotoxic T cell
Tissue
Adaptive
Disease
–

Applications

Cancer Organoid

Colorectal Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Breast Cancer

Cholangiocarcinoma

Gastric Cancer

Ovarian Cancer

Request a Quote
Inquiry

Description

Table of Contents
Request a Quote
▲ Back to top

Characteristics

Evaluation of the efficacy of an immunotherapeutic agent targeting cytotoxic T cells is possible by co-culturing specific organoids with Primed Cytotoxic T cells, allowing for the selective elimination of particular organoids.
This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.
Play Video

Principle

Drug Efficacy Evaluation in Co-culture of Tumor Organoids and Cytotoxic T Cell

PD L1 binds to PD 1 and inhibits T cell kiling of tumor cell

Blocking PD L1 or PD 1 allows T cell kiling of tumor cell

When evaluating the efficacy of atezolizumab in co-culture conditions with tumor organoids and tumor-infiltrating lymphocytes or tumor organoids and T cells derived from PBMCs, higher tumor organoid killing was observed in conditions without co-culture with tumor-infiltrating lymphocytes or T cells.
The method of evaluating efficacy by treating a specific mixture of tumor organoids and tumor-infiltrating lymphocytes with anticancer drugs is still at the research level globally, and our company uniquely holds patents and commercialization services related to this. Make your research shine brighter through the only service of its kind in the world.

Read out

Organoid-Based Immunotherapy Evaluation for Anticancer drugs

High Responder to control

Low Responder to control

Our cutting-edge platform brings approach in drug development, empowering clinicians and researchers to transcend beyond the binary classification of responders versus non-responders.
It facilitates a deeper examination of patient-specific responses to approved control drugs at various concentrations.
This technology illuminates the intricate interplay between genetic, regional, and environmental factors and their impact on drug efficacy, providing a path to address the pressing unmet needs in before clinical trail.

This example showcases the potential utility of our platform in identifying optimal partners for combination therapy with Immune Checkpoint Inhibitors (ICIs).
His suggests that Combination B could be a more effective strategy in enhancing the efficacy of ICIs.
This platform is designed to facilitate such discoveries, offering a clear pathway to improve clinical outcomes through strategic drug pairing.

AF Solution

Resources

Lambda

BioArt

Lambda Biologics

Lambda Biologics

Contact

+49 (0) 152 293 76591

info@lambdabiologics.com​

Deutscher Platz 5c

04103 Leipzig

Germany

@ 2024 . All rights reserved

Privacy Policy

Term of Services

Cookie Settings

Deutscher Pl. 5c

04103 Leipzig

Germany

@ 2024 . All rights reserved

Privacy Policy
Term of Services
Cookie Settings

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.